Roundup® Class Settlement - February 2026 Agreement

The proposed settlement was filed in the 22nd Judicial Circuit Court, City of St. Louis, Missouri on Feb. 17, 2026. If approved by the Court, the class settlement will:

• Require defendants to pay up to $7.25 billion over 17-21 years
• Address two distinct classes comprised of “current” claimants (individuals with a NHL diagnosis prior to 2/13/26) and “future” claimants (individuals exposed to Roundup but not diagnosed at the time of the settlement)
• Recognize both residential and occupational exposures to the product
• Tier class members based on whether they were exposed at home or at work, how aggressive their cancer is, and their age at the time of diagnosis
• Allow both current and future claimants to exercise their right to opt out of the settlement and pursue their case individually in the court system
• Include safeguards to help preserve the fund even in the event of bankruptcy or other financial issues encountered by Bayer

Here are the court documents.

• Exhibit 1: Court-Filed Settlement Agreement
• Exhibit 1. A: Roundup Products
• Exhibit 1. B: Non-Hodgkin Lymphoma Subtypes
• Exhibit 1. C: Roundup Product Manufacturers
• Exhibit 1. D: Release of Claims Form
• Exhibit 1. E: Full Settlement Notice
• Exhibit 1. F: Settlement Class Short-Form Annual Notice
• Exhibit 1. G: Proposed Preliminary Approval Order
• Exhibit 1. H: Proposed Final Order and Judgment
• Exhibit 1. I: Placeholder Pending Motion to File Under Seal

Review the court-filed proposed national Roundup class settlement agreement.

Review other related documents and more.

Since 2015, claims have been filed involving hundreds of thousands of plaintiffs. Two dozen cases have been tried to verdict in multiple jurisdictions resulting in eleven plaintiff verdicts. Motley Rice represents thousands of people diagnosed with non-Hodgkin’s lymphoma, a group of blood cancers that develop in the white blood cells of the immune system.

Read more about Roundup litigation.